Table 3.
Treatment-relatedlateadverseeventrates
RT + cisplatin | RT + cisplatin + cetuximab | P value | |
---|---|---|---|
Any late (>90 d from start of RT) | (n = 432) | (n = 416) | |
Grade 3–4 any adverse event | 57.4% | 61.3% | .26 |
Grade 3–4 dysphagia | 39.6% | 38.2% | |
Grade 3–4 radiation mucositis | 5.3% | 7.0% | |
Grade 3–4 mucositis/stomatitis (clinical examination): pharynx | 4.9% | 6.0% | |
Grade 3–4 hearing impaired | 6.0% | 5.0% | |
Grade 3–4 weight decreased | 7.6% | 8.7% | |
Grade 3–4 osteonecrosis | 6.0% | 4.8% | |
Grade 2–3 dry mouth | 47.0% | 45.9% |